Iovance Biotherapeutics, Inc. (IOVA) 

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Show less

Over the last 12 months, insiders at Iovance Biotherapeutics, Inc. have bought $74.89M and sold $0 worth of Iovance Biotherapeutics, Inc. stock.

On average, over the past 5 years, insiders at Iovance Biotherapeutics, Inc. have bought $47.89M and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Rothbaum Wayne P. (director) — $72.25M. MCPEAK MERRILL A (director) — $4.69M. Dukes Iain D. (director) — $292,800.

The last purchase of 5,000,000 shares for transaction amount of $45.75M was made by Rothbaum Wayne P. (director) on 2024‑02‑20.